Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences' stock price increased by 74.01% over the past six months, but decreased by 11.51% in the past month. The company announced a $175 million equity financing in August 2025, expected to extend the company's cash runway into late 2027. Gilead Sciences Inc. exercised its option to license Assembly Bio's herpes programs. The company shifted its strategic focus away from Vebicorvir (VBR) and reduced its workforce in July 2025. Positive interim results from Phase 1b clinical studies of ABI-1179 and ABI-5366 were reported, showing reductions in viral shedding rate and genital lesions for recurrent genital herpes.

Assembly Biosciences' products are not yet commercialized, so there is no discernible demand seasonality for its products or services at this stage.

Assembly Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for viral diseases. The company is developing ABI-4334, a capsid assembly modulator for chronic Hepatitis B Virus (HBV), aiming for a functional cure. They are also developing helicase-primase inhibitors (HPIs), ABI-5366 and ABI-1179, for recurrent genital herpes, and ABI-6250, an orally bioavailable HDV entry inhibitor for Hepatitis Delta Virus (HDV). Additionally, they are advancing microbiome-based technology for targeted oral delivery of therapeutics to treat gastrointestinal infections and ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses.

Assembly Biosciences, Inc. is headquartered in South San Francisco, California. Broader operational locations or geographic market segmentation details are not readily available.

Assembly Biosciences generally holds a positive reputation among analysts, with consensus ratings ranging from "Moderate Buy" to "Strong Buy". Positive interim Phase 1b data for its helicase-primase inhibitor candidates and Gilead Sciences' licensing of Assembly Bio's herpes programs have positively impacted its reputation. The strategic pipeline refocus and workforce reduction in July 2025 could have been perceived negatively by some stakeholders.

Assembly Biosciences is primarily owned by institutional shareholders (78.92%) and insiders (77.15%), with a negligible percentage held by retail investors (0.00%). Gilead Sciences Inc. is the largest individual shareholder, owning 28.48% of the company. Other major holders include Ecor1 Capital Fund Qualified LP, Alexander Schornstein, Adam Zlotnick, Farallon Capital Management LLC, Ra Capital Management LP, Commodore Capital LP, Derek A. Small, Janus Henderson Group PLC, and Vanguard Group Inc.